Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma, Inc. is a development-stage biopharmaceutical company focused on treatments for solid tumors and metastatic cancer. The company is headquartered in Melbourne, Australia.

Its lead product candidate, PRP, is a formulation of proenzymes, the inactive precursors of the pancreatic enzymes trypsinogen and chymotrypsinogen. The approach is based on research suggesting that these proenzymes can selectively act on cancer stem cells and suppress the processes that allow tumors to grow, spread and recur, while sparing healthy tissue. Propanc has targeted indications such as pancreatic, ovarian and colorectal cancers, with an emphasis on preventing tumor recurrence and metastasis. The company also conducts research through academic collaborations to identify additional proenzyme-based therapies.

Propanc Biopharma's common stock trades on the Nasdaq market under the ticker PPCB.